SB225002

Overview

SB225002, a potent, selective and non-peptide CXCR2 antagonist, inhibits 125 I-IL-8 binding to CXCR2 with an IC 50 of 22 nM.

Application

Products | Products > Disease Areas > Autoimmune Disease | Products > Disease Areas > Arthritis | Products > Disease Areas > Gastric Cancer | Products > Disease Areas > Digestive System Cancer | Products > Disease Areas > Digestive System Inflammation | Products > Disease Areas > Rheumatoid Arthritis | Products > Disease Areas > Cancer | Products > Disease Areas > Inflammation or Immune System Disease | Products > Disease Areas > Digestive System Disease | Products > Disease Areas > Musculoskeletal and Skin Disease | Products > Disease Areas > Metabolic or Endocrine Disease | Products > Signaling Pathways > GPCR/G Protein | Products > Signaling Pathways > Immunology/Inflammation | Products > Research Areas > Inflammation/Immunology | Products > Research Areas > Endocrinology | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Immunotherapy | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > CXCR

Product Information

• Catalog No.: HY-16711
• CAS No.: 182498-32-4
• Molecular Formula: C13H10BrN3O4
• Molecular Weight: 352.14
• Purity: 99.90%
• Storage: 4°C, stored under nitrogen * In solvent : -80°C, 2 years; -20°C, 1 year (stored under nitrogen)
• Solubility: ≥ 2.5 mg/mL (7.10 mM); Clear solution
• Availability: In-stock

Source

Original product source